Lin et al. demonstrated that bortezomib activated the pro-survival PI3K/Akt pathway in GBM cells, and this proteasome inhibitor was only able to kill GBM cells upon the simultaneous pharmacological blockade of PI3K/Akt pathway activity [44]. Here, AKT1 is linked to glioblastoma.